Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$35.07

1.27 (3.76%)

16:50
11/04/19
11/04
16:50
11/04/19
16:50

Myriad Genetics drops 30% after deletion of CPT codes impacts revenue

"In the fiscal first-quarter, Myriad made approximately an $11 million reserve adjustment for hereditary cancer revenue due to lower cash collections from small payers as a result of the deletion of the current procedural terminology, CPT codes 81211 and 81213. As a result, the company has revised its revenue accrual rate, and is forecasting lower hereditary cancer rates for fiscal year 2020. Myriad will provide a detailed summary of the changes on its fiscal first-quarter 2020 earnings call. Hereditary cancer volumes grew at a double-digit growth rate on a year-over-year basis for both the company's oncology and women's health business units," said the company.

  • 04

    Nov

  • 06

    Nov

  • 13

    Nov

MYGN Myriad Genetics
$35.07

1.27 (3.76%)

09/24/19
PIPR
09/24/19
NO CHANGE
Target $40
PIPR
Neutral
Myriad competitor allowed to keep pharmacogenomic stoplight, says Piper Jaffray
Myriad Genetics competitor Genomind resumed including specific drug recommendations in physician reports following interaction with FDA, but only for physician clients as patient reports only include the genotype information, Piper Jaffray analyst William Quirk tells investors in a research note. While there remains considerable uncertainty in the pharmacogenomics landscape, the recent move by Genomind is a positive read through for Myriad's GeneSight, says the analyst. He points out that several industry groups are lobbying the FDA to reverse their recent action against pharmacogenomic Clinical Laboratory Improvement Amendments-certified labs. This suggests the GeneSight psychotropic test report could remain on market as is, contends Quirk. He keeps a Neutral rating on shares of Myriad Genetics.
09/25/19
LEHM
09/25/19
NO CHANGE
Target $22
LEHM
Underweight
Barclays, following 'regulatory breadcrumbs,' stays Underweight on Myriad
The most important debate for shares of Myriad Genetics remains potential regulatory action for GeneSight, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes recent "regulatory breadcrumbs" confirm the risks inherent in his Underweight thesis on Myriad shares. The most recent important update was a letter submitted by the American Clinical Laboratory Association to the FDA on September 18 saying that the ACLA is "Deeply Concerned by FDA Actions on Pharmacogenetic Testing," says Meehan. If the lab industry were having positive FDA dialogue, there would have been no need to publish a formal four-page letter raising concerns about the regulatory review taking place, contends the analyst. He believes potential premarket approval application review of the test would raise further regulatory risk for GeneSight.
09/26/19
BOFA
09/26/19
DOWNGRADE
BOFA
Underperform
Myriad Genetics downgraded to Underperform from Neutral at BofA/Merrill
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.

TODAY'S FREE FLY STORIES

ARQL

ArQule

$19.71

10.035 (103.77%)

, MRK

Merck

$88.71

-0.13 (-0.15%)

08:00
12/10/19
12/10
08:00
12/10/19
08:00
Downgrade
ArQule, Merck rating change  »

ArQule downgraded to…

ARQL

ArQule

$19.71

10.035 (103.77%)

MRK

Merck

$88.71

-0.13 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

PENN

Penn National

$23.00

-0.12 (-0.52%)

08:00
12/10/19
12/10
08:00
12/10/19
08:00
Recommendations
Penn National analyst commentary  »

Penn National price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$266.93

-3.75 (-1.39%)

08:00
12/10/19
12/10
08:00
12/10/19
08:00
Options
Apple put buyer realizes 28% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKR

Timken

$53.50

(0.00%)

07:58
12/10/19
12/10
07:58
12/10/19
07:58
Conference/Events
Timken to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RHP

Ryman Hospitality

$89.28

-0.6 (-0.67%)

07:58
12/10/19
12/10
07:58
12/10/19
07:58
Syndicate
Ryman Hospitality 3M share Spot Secondary priced at $85.60 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CHD

Church & Dwight

$70.33

0.04 (0.06%)

07:57
12/10/19
12/10
07:57
12/10/19
07:57
Downgrade
Church & Dwight rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWR

New Relic

$69.03

0.4 (0.58%)

07:56
12/10/19
12/10
07:56
12/10/19
07:56
Conference/Events
New Relic to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CHWY

Chewy

$24.17

-0.76 (-3.05%)

07:56
12/10/19
12/10
07:56
12/10/19
07:56
Recommendations
Chewy analyst commentary  »

Chewy short-term pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

07:55
12/10/19
12/10
07:55
12/10/19
07:55
Conference/Events
FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting »

The Committee discusses…

THS

TreeHouse

$51.68

0.16 (0.31%)

07:55
12/10/19
12/10
07:55
12/10/19
07:55
Conference/Events
TreeHouse to host investor meeting »

Investor breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ALB

Albemarle

$64.71

0.405 (0.63%)

07:54
12/10/19
12/10
07:54
12/10/19
07:54
Conference/Events
Albemarle to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DVN

Devon Energy

$23.15

-0.005 (-0.02%)

, HES

Hess Corp.

$61.75

-0.505 (-0.81%)

07:54
12/10/19
12/10
07:54
12/10/19
07:54
Recommendations
Devon Energy, Hess Corp., Vermilion Energy, Concho Resources, EOG Resources, Diamondback Energy, Parsley Energy, Pioneer Natural, WPX Energy analyst commentary  »

JPMorgan upgrades Devon…

DVN

Devon Energy

$23.15

-0.005 (-0.02%)

HES

Hess Corp.

$61.75

-0.505 (-0.81%)

VET

Vermilion Energy

$14.89

0.13 (0.88%)

CXO

Concho Resources

$76.50

0.01 (0.01%)

EOG

EOG Resources

$74.51

0.52 (0.70%)

FANG

Diamondback Energy

$83.79

0.56 (0.67%)

PE

Parsley Energy

$16.25

0.03 (0.18%)

PXD

Pioneer Natural

$133.20

-0.71 (-0.53%)

WPX

WPX Energy

$10.57

0.06 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMRX

Chimerix

$2.54

0.07 (2.83%)

07:51
12/10/19
12/10
07:51
12/10/19
07:51
Hot Stocks
Chimerix presents DSTAT program data at ASH »

Chimerix announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$55.79

-0.36 (-0.64%)

07:51
12/10/19
12/10
07:51
12/10/19
07:51
Conference/Events
Delta Air Lines to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$30.44

16.04 (111.39%)

07:49
12/10/19
12/10
07:49
12/10/19
07:49
Recommendations
Forty Seven analyst commentary  »

Forty Seven price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKU

BankUnited

$35.53

0.07 (0.20%)

07:48
12/10/19
12/10
07:48
12/10/19
07:48
Initiation
BankUnited initiated  »

BankUnited initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXGN

NextGen Healthcare

$18.15

0.24 (1.34%)

07:48
12/10/19
12/10
07:48
12/10/19
07:48
Conference/Events
NextGen Healthcare to host analyst day »

Analyst day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CG

Carlyle Group

$29.17

-0.36 (-1.22%)

07:46
12/10/19
12/10
07:46
12/10/19
07:46
Initiation
Carlyle Group initiated  »

Carlyle Group reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MET

MetLife

$49.57

0.065 (0.13%)

07:45
12/10/19
12/10
07:45
12/10/19
07:45
Conference/Events
MetLife to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RDFN

Redfin

$20.77

-0.46 (-2.17%)

07:45
12/10/19
12/10
07:45
12/10/19
07:45
Upgrade
Redfin rating change  »

Redfin upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

07:44
12/10/19
12/10
07:44
12/10/19
07:44
Hot Stocks
Bristol-Myers presents OS, safety data from pivotal CC-486 study QUAZAR AML-001 »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CONN

Conn's

$20.51

1.08 (5.56%)

07:43
12/10/19
12/10
07:43
12/10/19
07:43
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

LULU

Lululemon

$231.08

1.58 (0.69%)

07:42
12/10/19
12/10
07:42
12/10/19
07:42
Recommendations
Lululemon analyst commentary  »

Lululemon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GOLD

Barrick Gold

$16.85

-0.045 (-0.27%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Barrick Gold to sell 90% interest in Massawa project to Teranga for up to $430M »

Barrick Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$62.68

-1.77 (-2.75%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Sage Therapeutics announces planned progression of SAGE-718 »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.